Pooled placebo (n=12) | Anifrolumab | |||
300 mg SC (n=6) | 300 mg IV (n=6) | 600 mg SC (n=6) | ||
Any AE, n (%) | 4 (33) | 3 (50) | 2 (33) | 4 (67) |
Any AE (with an outcome of death), n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Any serious AE*, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Any AE causing discontinuation of product, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
*Includes events with an outcome of death.
AE, adverse event; IV, intravenous; SC, subcutaneous.